Skip to main content
. 2021 Mar 29;9(3):335–344. doi: 10.14218/JCTH.2020.00164

Fig. 3. Pooled odds ratios (ORs) of virological response in tenofovir disoproxil fumarate (TDF)-treated vs. entecavir (ETV)-treated chronic hepatitis B (CHB) patients.

Fig. 3

After (A) 12 weeks, (B) 24 weeks, (C) 36 weeks, (D) 48 weeks, (E) 72 weeks and (F) 96 weeks of treatment. CHB, chronic hepatitis B; ETV, entecavir; OR, odds ratio; TDF, tenofovir disoproxil fumarate.